WWM
SRPT icon

Wolff Wiese Magana’s Sarepta Therapeutics SRPT Stock Holding History

Wolff Wiese Magana’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-55
Closed -$941 – 1034
2025
Q2 		$941 Hold
55
– – ﹤0.01% 850
2025
Q1 		$3.51K Sell
55
-46
-46% -$4.84K ﹤0.01% 641
2024
Q4 		$12.3K Sell
101
-44
-30% -$5.39K 0.01% 385
2024
Q3 		$18.1K Buy
145
+40
+38% +$5.53K 0.01% 330
2024
Q2 		$16.6K Hold
105
– – 0.01% 256
2024
Q1 		$13.6K Hold
105
– – 0.01% 260
2023
Q4 		$10.1K Buy
+105
New +$10.1K 0.01% 282

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Wolff Wiese Magana's SRPT Position: Q3 2025 in Review

Wolff Wiese Magana sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 55 shares — an estimated $941 sold.

Wolff Wiese Magana first reported a position in SRPT in Q4 2023 and held it in 7 quarters. The position peaked at $18.1K in Q3 2024. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Wolff Wiese Magana reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Wolff Wiese Magana sold 55 Sarepta Therapeutics shares in Q3 2025, an estimated $941.
  • Wolff Wiese Magana first reported a position in Sarepta Therapeutics in Q4 2023 and held it in 7 quarters.
  • Wolff Wiese Magana's Sarepta Therapeutics position peaked at $18.1K in Q3 2024.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Wolff Wiese Magana's 13F filing for Q3 2025, filed 28 Oct 2025.